卵巢癌2009 nccn指南（中文版）

Copyright © National Comprehensive Cancer Network 2009. All rights reserved. “NCCN”, the NCCN logo, and “National Comprehensive Cancer Network” are registered trademarks of the National Comprehensive Cancer Network. The Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Ovarian Cancer Guideline 2009 is the Chinese adapted version of NCCN Clinical Practice Guidelines in Oncology-Ovarian Cancer Guideline, V.2.2009 as permitted and endorsed by NCCN. It is the collaborative outcome of the National Comprehensive Cancer Network and Chinese key opinion leaders of the field.The original guideline and Chinese edition are both available at: http:/www.nccn.org. To view the most recent and complete version of the guideline, go online to www.nccn.org. These Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN.These Guidelines are a work in progress that will be refined as often as new significant data becomes available. The NCCN Guidelines are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN guideline is expected to use independent medical judgment in the context of individual clinical circumstance to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.This publication should not be used for commercial purpose. It is provided for free to Chinese medical professions with the support of the unrestrictive educational grant of GlaxoSmithKline (China) Investment Co., Ltd. which exerts no influence to the formation of the Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Ovarian Cancer Guideline 2009.NCCN ®肿瘤学临床实践指南(中国版) 2009年 第一版© National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. The Chinese edition 2009 is the collaborative outcome of the National Comprehensive Cancer Network and Chinese key opinion leaders of the field. Translated and adapted with permission and endorsement from the National Comprehensive Cancer Network. To view the most recent and complete version of this or any other guideline, visit www.nccn.org.卵巢癌NCCN卵巢癌专家组成员* Robert J. Morgan, Jr., MD/Chair City of Hope Comprehensive Cancer CenterRonald D. Alvarez, MD University of Alabama at Birmingham Comprehensive Cancer CenterDeborah K. Armstrong, MD The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBarry Boston, MD £ St. Jude Childrens Hospital/University of Tennessee Cancer InstituteRobert Burger, MD Fox Chase Cancer CenterLee-may Chen, MD UCSF Helen Diller Family Comprehensive Cancer CenterLarry Copeland, MD Arthur G. James Cancer Hospital 105:35-41. 见讨论。b Goff BA, Mandel L, Drescher CW, et al. Cancer 2007;109:221-7.c 标准建议应该包括由妇科肿瘤医生对患者的评估。已发表的资料显示由妇科肿瘤医生实施的初次评估和细胞减灭术可使患者生存受益。d 见初次手术原则（OV-A）。e 见化疗原则（OV-B）和过敏反应的处理（OV-C）。OV-1NCCN ®上皮性卵巢癌/输卵管癌/原发性腹膜癌肿瘤学临床实践指南(中国版) 2009年 第一版© National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. The Chinese edition 2009 is the collaborative outcome of the National Comprehensive Cancer Network and Chinese key opinion leaders of the field. Translated and adapted with permission and endorsement from the National Comprehensive Cancer Network. To view the most recent and complete version of this or any other guideline, visit www.nccn.org.c 标准建议应该包括由妇科肿瘤医生对患者的评估。已发表的资料显示由妇科肿瘤医生实施的初次评估和细胞减灭术可使患者生存受益。d 见初次手术原则（OV-A）。e 见化疗原则（OV-B）和过敏反应的处理（OV-C）。f 透明细胞癌为G3。g 根据妇科肿瘤医生的临床判断，手术可在6个周期化疗后实施。OV-2经既往手术确诊 结果 初始治疗cNCCN ®肿瘤学临床实践指南(中国版) 2009年 第一版© National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. The Chinese edition 2009 is the collaborative outcome of the National Comprehensive Cancer Network and Chinese key opinion leaders of the field. Translated and adapted with permission and endorsement from the National Comprehensive Cancer Network. To view the most recent and complete version of this or any other guideline, visit www.nccn.org.上皮性卵巢癌/输卵管癌/原发性腹膜癌病理分期 初始化疗/初始辅助治疗hd 见初次手术原则（OV-A）。e 见化疗原则（OV-B）和过敏反应的处理（OV-C）。f 透明细胞癌为G3。h 接受初始化疗的患者应进行如下监测随访：1.至少每2个周期行1次盆腔检查 2.如有指征，进行全血细胞计数（包括血小板） 3.如有指征，进行生化检查 4.于每周期化疗前行CA-125或根据临床指征行其他肿瘤标志物检查 5.如有指征，进行影像学检查OV-3i 方案： 1.紫杉醇135 mg/m2，24小时IV，d1；顺铂100 mg/m2，IP，于紫杉醇静脉用药结束之后（d2）； 紫杉醇60 mg/m2（体表面积上限为2.0 m2），IP，d8。每3周重复，共6个周期。（1类）